Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C44H60FN3O10 |
Molecular Weight | 809.9597 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)[C@@H]2[C@@H](CC[C@H](O)C3=CC=C(F)C=C3)C(=O)N2C4=CC=C(CNC(=O)CCCCCCCCCCC(=O)NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C=C4
InChI
InChIKey=JGNXLPQJHVVQHB-GXPLPOFXSA-N
InChI=1S/C44H60FN3O10/c1-58-34-22-16-31(17-23-34)41-35(24-25-36(50)30-14-18-32(45)19-15-30)44(57)48(41)33-20-12-29(13-21-33)26-46-39(53)10-8-6-4-2-3-5-7-9-11-40(54)47-27-37(51)42(55)43(56)38(52)28-49/h12-23,35-38,41-43,49-52,55-56H,2-11,24-28H2,1H3,(H,46,53)(H,47,54)/t35-,36+,37+,38-,41-,42-,43-/m1/s1
Molecular Formula | C44H60FN3O10 |
Molecular Weight | 809.9597 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Canosimibe is diphenyl azetidinone patented by German pharmaceutical company Aventis Pharma Deutschland GmbH as hypolipidemic agent. Canosimibe acts as pre-systemic inhibition of intestinal cholesterol absorption. Unfortunately, during phase II clinical trials Canosimibe failed to demonstrate efficacy in in patients with primary severe hypercholesterolemia.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00718965
50 mg/day
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:19:46 GMT 2023
by
admin
on
Fri Dec 15 17:19:46 GMT 2023
|
Record UNII |
2GG0K1I5CI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29703
Created by
admin on Fri Dec 15 17:19:46 GMT 2023 , Edited by admin on Fri Dec 15 17:19:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2GG0K1I5CI
Created by
admin on Fri Dec 15 17:19:46 GMT 2023 , Edited by admin on Fri Dec 15 17:19:46 GMT 2023
|
PRIMARY | |||
|
9077
Created by
admin on Fri Dec 15 17:19:46 GMT 2023 , Edited by admin on Fri Dec 15 17:19:46 GMT 2023
|
PRIMARY | |||
|
9875746
Created by
admin on Fri Dec 15 17:19:46 GMT 2023 , Edited by admin on Fri Dec 15 17:19:46 GMT 2023
|
PRIMARY | |||
|
768394-99-6
Created by
admin on Fri Dec 15 17:19:46 GMT 2023 , Edited by admin on Fri Dec 15 17:19:46 GMT 2023
|
PRIMARY | |||
|
C91027
Created by
admin on Fri Dec 15 17:19:46 GMT 2023 , Edited by admin on Fri Dec 15 17:19:46 GMT 2023
|
PRIMARY | |||
|
100000175416
Created by
admin on Fri Dec 15 17:19:46 GMT 2023 , Edited by admin on Fri Dec 15 17:19:46 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|